This review is based on the Croom Lecture delivered by Dr Riches at the RCPE Updates in Internal Medicine Symposium on 23 October 2009.
Keywords Osteoporosis, osteoprotegerin, RANK, RANK ligand
Declaration of Interests The authors have submitted a patent application on the use of osteoprotegerin antibodies as a diagnostic test and therapeutic target in patients with osteoporosis. Professor Ralston has received consulting fees from Procter & Gamble and Novartis and Merck, lecture fees from Novartis and Procter & Gamble and grant support from Novartis and Wyeth.
